Australia's Uscom jumps as BP monitor enters final review phase in China

USCOM

29/03/2021 04:15

** Shares of Uscom Ltd  UCM.AX  climb as much as 5.9% to
A$0.180, their highest since Feb. 24
    ** The medical device maker says its BP+ non-invasive
central blood pressure monitor has entered the final review
phase of China NMPA regulatory approval  urn:newsml:reuters.com:*:nASX4FzD1n
    ** Adds the final NMPA approval is expected by April to
August 2021
    ** Stock had gained 6.3% this year, as of last close

 (Reporting by Yamini C S)
 ((Yamini.CS@thomsonreuters.com;))